BioAtla에 대한 매도 수량은 투자자에게 BioAtla의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

BioAtla (NASDAQ:BCAB) 주식, 공매도 수량 보고

BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Asia

Equities

News

Global

Markets

ACIC

AMZN

BABA

BCAB

BIDU

FOUR

GOOG

GOOGL

OLPX

REAL

2008년 금융 위기 이전 주택 시장에 대한 선견지명 있는 투자로 유명한 유명 투자자 마이클 버리(Michael Burry)는 2024년 2분기에 자신의 헤지 펀드 포트폴리오에 큰 변화를 주었다.

&#39;빅쇼트&#39; 명성의 마이클 버리, 중국에 큰 투자하고 알리바바를 최대 보유 주식으로 공개

BioAtla Inc

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $65 price target.

Price Target

Reiteration

Analyst Ratings

HALO

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target

Traders are cautiously optimistic ahead of the all-important payrolls report, with the index futures narrowly mixed in early Friday. The <a href="https://www.benzinga.com/news/24/10/41177060/port-strike-ends-workers-return-to-work-friday">suspension of the Longshoremen&#8217;s strike</a> removes one of the overhangs even as the Middle East tensions rage unabated. The September job gains could have a big impact on the near-term direction of the market.
&#8220;Payroll data will be closely watched as the sentiment is now that the Fed has become less focused on inflation and more on employment,&#8221; said fund manager Louis Navellier. A BofA note highlighted that the S&amp;P 500 futures have been more reactive to non-farm payroll data than any other economic data in recent years, a screenshot of the note shared by a financial writer on X showed.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.14%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.07%</td>
</tr>
<tr>
<td>Dow</td>
<td>-0.05%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.22%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) gained 0.16% to $568.75 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) moved 0.32% higher to $483.14, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks showed nervousness throughout Thursday&#8217;s session before closing lower, with geopolitical tensions, the dockworkers&#8217; strike and mixed economic data weighing down on sentiment. While a bigger-than-expected increase in jobless claims stirred anxiety about the monthly jobs data, the Institute for Supply Management&#8217;s stronger-than-expected service sector purchasing managers&#8217; index tempered expectations concerning a bigger cut.
The Nasdaq Composite oscillated back and forth in the morning session but languished mostly below the unchanged line in the afternoon before ending marginally lower. This is despite IT and communication services posting moderate gains. The broader S&amp;P 500 Index traded mostly in the red and ended modestly lower, with consumer discretionary, consumer staple, healthcare, material and real estate stocks dragging the index lower. On the other hand, energy stocks posted solid gains. The index settled at a two-week low. 
The 30-stock Dow Jones Industrial Average underperformed as it settled down 0.44% at a one-week low.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.04%</td>
<td>17,918.47</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>-0.17%</td>
<td>5,699.94</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>-0.44%</td>
<td>42,011.59</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.09%</td>
<td>2,195.01</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Comerica Chief Economist Bill Adams said he expects the Fed to cut rates by 25 basis points in November, December, January and March and then move toward quarterly rate cuts for the rest of the next year. The economist noted that inflation is slowing to near the Fed&#8217;s 2% target, largely due to lower energy prices. Core inflation, though higher than the headline inflation, could slow due to downward pressure on durable goods and used autos persist and a slower increase in housing costs, he said.
Adams sees the Fed funds rate to be in the range of 3%-3.25% by the end of 2025. That said, the economist does not rule out a faster pace of rate cuts if the economy weakens materially, or a slower rate cut if the large deficit or wars in oil-exporting regions cause inflation to rebound.
Navellier weighed in on the near-term trajectory of the market in a note sent to clients on Thursday. &#8220;Funds flows into equities are likely to remain positive, at least until there is a sustained pullback, which hasn&#8217;t happened since &#8217;22,&#8221; he said.
The fund manager noted that the AI theme got a boost after OpenAI&#8217;s new funding round, which raised $6.6 billion from a long list of well-known investors, valuing the company at $157 billion. Also, Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang&#8217;s comments that demand for the company&#8217;s new Blackwell chips is &#8220;insane,&#8221; is a positive for the sector, he said.
 &#8220;AI adoption remains one of the fastest-growing new technologies ever and continues to promise big gains in productivity, though the timing of meaningful cash flow gains still remains uncertain,&#8221; he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures-on-thinkorswim">How To Trade Futures</a>
Upcoming Economic Data:
<ul>
<li>The Bureau of Labor Statistics is due to release its September non-farm payrolls report at 8:30 a.m. EDT. Economists, on average, expect job gains of 150,000, up from the 142,000 rate in August. The jobless claims are expected to stay put at 4.2% and the average hourly wages may have risen at a steady annual pace of 3.8%.</li>
<li>New York Fed President John Williams is scheduled to give opening remarks at the conference &#8220;The Future of New York City: Focus on Jobs,&#8221; at 9 a.m. EDT.</li>
<li>Chicago Fed President Austan Goolsbee will make a TV appearance at 10 a.m. EDT.</li>
</ul>
Stocks In Focus:
<ul>
<li>Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) plunged over 37% after reports said the low-cost carrier is exploring Chapter 11 bankruptcy filing following its failed attempt to merge with JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>). JetBlue climbed over 5%.</li>
<li>Apogee Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) is scheduled to <a href="https://www.benzinga.com/calendars/earnings">announce its quarterly results before the market opens.</a></li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures added to their 5%+ gains from Thursday and traded above $74.50, and gold futures traded flat under their all-time high. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) climbed over 1% ahead of the jobs data. The yield on the 10-year Treasury note remained unchanged at 3.85%.
The Asian markets were mixed, with Japan ending modestly higher, and Hong Kong and a few other majors advancing. On the other hand, the Indian, Australian, Malaysian, Indonesian, and Taiwanese markets retreated. The Chinese market continued to remain closed for a weeklong holiday.
In Europe, sentiment is modestly positive in early trading, although the U.K. market is retreating.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41179608/mark-zuckerberg-bulldozes-past-jeff-bezos-to-become-worlds-2nd-richest-person-as-meta-stock-soar">Mark Zuckerberg Bulldozes Past Jeff Bezos To Become World&#8217;s 2nd Richest Person As Meta Stock Soars: Is Musk&#8217;s Top Spot In Jeopardy?</a></li>
</ul>
Image Created By Midjourney

Earnings

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

Movers

$BTC

APOG

JBLU

NVDA

SAVE

US Stocks On Edge As Traders Brace For Crucial Jobs Report: Why This Fund Manager Says AI Stocks Just Received Big Boost

Guidance

Apogee Enterprises Raised FY25 Adj. EPS To $4.90-$5.20 From $4.65-$5.00 Vs. Cons. $4.82

Needham analyst Joshua Reilly reiterates Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) with a Buy and maintains $25 price target.

JAMF

Needham Reiterates Buy on Jamf Holding, Maintains $25 Price Target

Apogee Enterprises Reaffirmed FY25 Outlook For Net Sales To Decline 4% to 7%

Apogee Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) reported quarterly earnings of $1.44 per share which beat the analyst consensus estimate of $1.23 by 17.07 percent. The company reported quarterly sales of $342.440 million which beat the analyst consensus estimate of $335.289 million by 2.13 percent. This is a 3.18 percent decrease over sales of $353.670 million the same period last year.

Earnings Beats

Apogee Enterprises Q2 2025 Adj. EPS $1.44 Beats $1.23 Estimate, Sales $342.440M Beat $335.289M Estimate

EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has reportedly begun inviting <a href="https://www.benzinga.com/topic/tesla-cybertruck">Cybertruck</a> reservation holders to configure their cheaper non-foundation series version of the vehicle.
What Happened: The news was first flagged on social media platform X by Tesla enthusiast Sawyer Merritt. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING: Tesla has officially begun inviting people to order the less expensive non-Foundation Series Cybertrucks! It starts at $79,990. The $99,990 ti-motor Cyberbeast is also now available to order. Production of cheaper Cybertrucks is finally about to start! <a href="https://t.co/mTFUbZu1MK">pic.twitter.com/mTFUbZu1MK</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1842049199145205957?ref_src=twsrc%5Etfw">October 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The foundation series of the Cybertruck refers to the limited-edition version of the stainless steel truck with exclusive badges and premium accessories being manufactured by the company for the initial months of starting deliveries. The foundation series Cybertruck starts at $99,990 for the base version. 
The non-foundation series Cybertruck, though less exclusive, will be cheaper. The base version of the non-foundation series Cybertruck starts at $79,990 with the higher-end Cyberbeast variant starting at $99,990. 
The invites to reservation holders imply that Tesla might soon start production of the non-foundation series version. The company did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga&#8217;s</a> request for comment.
Why It Matters: Tesla started delivering the Cybertruck in November 2023.
During Tesla's annual shareholder meeting in early June, Tesla CEO Elon Musk said that the company has touched a weekly production record of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36039263/did-tesla-overpromise-and-underdeliver-with-the-cybertruck" target="_blank" rel="noreferrer noopener">1,300 Cybertrucks</a>. The company is now ramping production further to touch 2,500 units per week by the end of the year to deliver 250,000 Cybertrucks a year starting in 2025.
Cybertruck&nbsp;<a href="https://www.benzinga.com/news/24/07/39876213/tesla-confirms-it-aims-to-start-selling-cybertruck-in-canada-this-year-pre-orders-open-for-150" target="_blank" rel="noreferrer noopener">production is on track</a>&nbsp;to achieve profitability by the end of the year, the company said during its second-quarter earnings in July.
In the three months through the end of September, Tesla delivered 22,915 units of the Model X, Model S, and Cybertruck together. The company doesn&#8217;t provide a Model-wise breakdown of deliveries. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41135581/tesla-discontinues-cheapest-model-3-variant-entry-level-trim-now-starts-at-42-490" target="_blank" rel="noreferrer noopener">Tesla Discontinues Cheapest Model 3 Variant: Entry Level Trim Now Starts At $42,490</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Reportedly Starts Inviting Reservation Holders To Order More Affordable Non-Foundation Series Cybertruck

WIIM

RIVN

Rivian shares are trading lower after the company lowered its annual production guidance due to supply shortage of shared component on the R1 and RCV platforms.

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy and maintains $73 price target.

LEGN

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target

Masayoshi Son, CEO of SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>), has forecasted the <a href="https://www.benzinga.com/markets/24/09/40836225/human-like-reasoning-strawberry-ahead-aggressive-nvidia-buying-hotter-inflation-data">advent of artificial superintelligence</a> within the next ten years. This revelation was shared during the SoftBank World 2024 conference.
What Happened: Son, Japan&#8217;s second wealthiest individual, commended OpenAI for its recent technological strides. He specifically mentioned the new GPT-o1 models, codenamed &#8220;Strawberry,&#8221; which he believes have developed reasoning capabilities, <a href="https://observer.com/2024/10/softbank-masayoshi-son-ai-openai-investment/">reported</a> the Observer on Friday. 
"This technology will evolve to a point&nbsp;where your happiness will be its greatest reward," said Son. He claimed that ASI, which would be 10,000 times more powerful than human intelligence, could be achieved within a decade.
Son envisions a future where AI can perform everyday tasks, such as grocery shopping and investment management, ultimately enhancing human happiness. His optimistic outlook is consistent with his history of making bold tech investments.
Looking forward, Son anticipates the achievement of artificial general intelligence, which matches human intelligence, within two to three years. 
He also predicts artificial superintelligence, surpassing human capabilities, within a decade. SoftBank&#8217;s AI strategy is centered around ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), a U.K.-based chip designer, with plans to expand into AI chips, data centers, and industrial robots.
See Also: <a href="https://www.benzinga.com/news/24/09/41020589/tech-youtuber-mkbhd-responds-after-facing-massive-backlash-over-his-new-12-a-month-wallpaper-app?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tech YouTuber MKBHD Responds After Facing Massive Backlash Over His New $12 A Month Wallpaper App</a>
Why It Matters: Son&#8217;s prediction comes amid <a href="https://www.benzinga.com/markets/24/09/40836225/human-like-reasoning-strawberry-ahead-aggressive-nvidia-buying-hotter-inflation-data">growing interest</a> in A.I. advancements, particularly with OpenAI&#8217;s &#8220;Strawberry&#8221; models. These models are noted for their human-like reasoning capabilities, which could revolutionize various industries.
However, <a href="https://www.benzinga.com/news/24/08/40387488/masayoshi-sons-plans-to-rival-nvidia-with-softbanks-own-ai-chip-production-hit-a-roadblock-as-intel">SoftBank&#8217;s ambitions</a> to rival NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in A.I. chip production reportedly faced setbacks when talks with Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) fell through. Despite this, SoftBank is exploring partnerships with other manufacturers like Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Additionally, Son&#8217;s focus on AI aligns with Sam Altman&#8216;s commitment to <a href="https://www.benzinga.com/news/24/05/38608040/openais-sam-altman-says-were-making-agi-and-it-will-be-worth-it-dont-care-if-we-burn-500m-or-50b">developing artificial general intelligence</a>, regardless of the financial cost. This shared vision underscores the significant investments and strategic shifts occurring in the A.I. sector.
Interestingly, SoftBank&#8217;s past decision to sell its Nvidia shares in 2019 resulted in a missed opportunity, as those shares would <a href="https://www.benzinga.com/general/24/06/39489510/the-150-billion-opportunity-softbank-lost-by-selling-nvidia-shares-too-soon">now be approximately worth over $150 billion</a>. This highlights the high stakes and rapid evolution of the AI and tech investment landscape.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41087674/openais-searchgpt-set-to-disrupt-googles-search-empire-as-former-engineer-sounds-alarm-on-deteriorat?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">OpenAI&#8217;s SearchGPT Set To Disrupt Google&#8217;s Search Empire As Former Engineer Sounds Alarm On Deteriorating User Experience Amid Rising Competition</a></li>
</ul>
Image Via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

INTC

SFTBF

SFTBY

SoftBank's Masayoshi Son Predicts Artificial Superintelligence Within A Decade After Testing OpenAI's 'Strawberry' Models

The company is also reaffirming its annual delivery&nbsp;outlook&nbsp;of low single digit growth as compared to 2023, which it expects to be in a range of 50,500 to 52,000 vehicles.
Rivian is experiencing a production disruption due to a shortage of a shared component on the R1 and RCV platforms. This supply shortage impact began in&nbsp;Q3&nbsp;of this year, has become more acute in recent weeks and continues.

Rivian Revises Annual Production Guidance To Be 47,000 - 49,000 Vehicles (Prior 57,000), Citing Supply Shortage

Wolfe Research analyst Bill Carcache upgrades M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) from Peer Perform to Outperform and announces $210 price target.

Upgrades

Wolfe Research Upgrades M&T Bank to Outperform, Announces $210 Price Target

EXAS

Exact Sciences Says FDA Approves Exact Sciences' Cologuard Plus Test, Setting New Benchmark In Non-Invasive Colorectal Cancer Screening, Company Expects To Launch Cologuard Plus Test With Medicare Coverage And Guideline Inclusion In 2025

Rivian Reports Q3 Production Of 13,157 Vehicles At Its Manufacturing Facility In Normal, Illinois and Delivery Of 10,018 Vehicles

IDYA

IDEAYA Biosciences Announces Late-Breaker Oral Presentation Of IDE397 Phase 1 Expansion Results In MTAP-Deletion Lung And Urothelial Cancer At 36th Edition EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics

RBC Capital analyst Tom Narayan downgrades Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) from Outperform to Sector Perform.

Downgrades

STLA

RBC Capital Downgrades Stellantis to Sector Perform

GEO Group Announces Exercise Of Five-Year Option Period For Adelanto ICE Processing Center Contract,  Through December 19, 2029

In the first phase of this partnership, the companies will integrate Waymo&#39;s sixth-generation fully autonomous technology &ndash; the Waymo Driver &ndash; into Hyundai&#39;s all-electric IONIQ 5 SUV, which will be added to the Waymo One fleet over time.

HYMTF

Hyundai Motor, Waymo Enter Multi-year Strategic Partnership

Macquarie analyst Eugene Hsiao downgrades Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) from Outperform to Neutral and raises the price target from $25 to $33.

Macquarie Downgrades Li Auto to Neutral, Raises Price Target to $33

Google by Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) is preparing to revolutionize its search experience with a host of new features powered by its Gemini AI models. These changes, announced on Friday, are set to take Google Search beyond its traditional format.
What Happened: The most notable update involves an AI-driven layout that organizes search results, giving prominence to videos, forum links, and widgets. Rhiannon Bell, Google&#8217;s vice president of user experience, described this as a &#8220;pretty dramatic shift&#8221; from previous designs. Initially, this will be applied to open-ended queries like recipe searches, with plans to expand to other topics.
The revamped search page will first be available on mobile devices, with expectations for future desktop integration. Bell emphasized that the new experience is designed for exploration and inspiration, particularly when no definitive answer exists.
See Also: <a href="https://www.benzinga.com/news/24/09/41086806/elon-musk-mocks-vinod-khosla-after-openai-investor-mixes-up-argentinas-poverty-and-unemployment-rate?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Mocks Vinod Khosla After OpenAI Investor Mixes Up Argentina&#8217;s Poverty And Unemployment Rates To Draw Parallels Between Javier Milei And Trump: &#8216;Vinod Is Just Actually Not Smart&#8217;</a>
Google will also enhance its Lens feature, allowing users to interact with their environment using their phone&#8217;s camera. Lens will now provide detailed information, including reviews and price comparisons, for shopping-related searches, which account for 20% of all Lens queries, as noted by product director Lou Wang.
Why It Matters: The introduction of these AI-driven features comes at a crucial time for Google. <a href="https://www.benzinga.com/news/events/24/05/38950304/googles-gemini-integrated-search-innovations-what-you-need-to-know">Google&#8216;s Gemini AI</a> additions were unveiled at its I/O Conference earlier this year, marking a strategic move to fend off rising competition from <a href="https://www.benzinga.com/news/24/09/41087674/openais-searchgpt-set-to-disrupt-googles-search-empire-as-former-engineer-sounds-alarm-on-deteriorat">OpenAI&#8216;s SearchGPT</a>. This new AI-driven search engine is poised to challenge Google&#8217;s longstanding dominance in the market.
Former Google engineer Arvind Jain, now CEO of Glean, has pointed out that Google&#8217;s focus on profitability has led to a decline in user experience, particularly on mobile devices where ads have become overwhelming. This has opened the door for new competitors, making Google&#8217;s latest AI innovations a timely response to maintain its competitive edge.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41111038/elon-musk-gets-bold-font-removed-from-xs-main-timeline-because-of-excessive-use-my-eyes-are-bleeding?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Gets Bold Font Removed From X&#8217;s Main Timeline Because Of &#8216;Excessive&#8217; Use: &#8216;My Eyes Are Bleeding&#8217;</a></li>
</ul>
Photo by Solen Feyissa on Unsplash
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

General

Google Search Set For 'Pretty Dramatic Shift' With Gemini AI Integration, Says Executive

Investors are constantly on the hunt for stocks that offer solid returns. However, finding these stocks can be challenging and sometimes expensive....

These 2 "Strong Buy" Penny Stocks Are Poised for a Big Rally, Say Analysts

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BioAtla (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcab-stock-quote/">BCAB</a>) just reported results for the second quarter of 2024.<ul><li>BioAtla reported earnings per share of -44 cents. This met the analyst estimate for EPS of -44 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bcab-stock-earnings-bioatla-for-q2-of-2024/">BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024

BioAtla GAAP EPS of -$0.44 in-line

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

BioAtla (BCAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni Benjamin from JMP Secur...

Reni Benjamin's Buy Rating for BioAtla: Strong Pipeline and Financial Health Signal Upside Potential

Michael Burry's Scion Asset sheds Safe Bulkers, adds Hudson Pacific, others in Q2

Justin Zelin, an analyst from BTIG, reiterated the Buy rating on BioAtla (BCAB – Research Report). The associated price target was raised to $13.00...

Buy Rating for BioAtla: Promising Pipeline and Strategic Partnerships Fuel Optimistic Outlook

Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on BioAtla (BCAB – Research Report), retaining the price target of $5.00. Reni Benj...

Buy Rating Affirmed for BioAtla on Strong Clinical Data and Solid Financial Positioning

BioAtla out-licenses BA3362 to Context Therapeutics

Analyst Justin Zelin of BTIG maintained a Buy rating on BioAtla (BCAB – Research Report), retaining the price target of $13.00. Justin Zelin has gi...

Buy Rating Affirmed for BioAtla Amidst Strategic Collaborations and Promising Clinical Catalysts

CNTX

CRMD

PHYS

SBLK

Press Releases

BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024

Health Care

BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Comments

BioAtla

매도 수량

BioAtla (NASDAQ:BCAB) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌